MedTrace Logo

A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases

NCT07249892 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2025-11-25

No results posted yet for this study

Summary

A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases

Conditions

  • Metastatic Solid Tumors

Interventions

DRUG

BPR-6023021 for injection

BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.

Sponsors & Collaborators

  • Beijing Quarkxia Technology Co., Ltd.

    collaborator UNKNOWN

  • Chengdu Syncor Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yan Yang · Chengdu Syncor Pharmaceutical Co., Ltd.

  • Wei Fan · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-19
Primary Completion
2027-07-30
Completion
2027-09-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07249892 on ClinicalTrials.gov